sacituzumab govitecan,atezolizumab,bevacizumab
gilead sciences,roche
['beat', 'breast', 'trodelvy', 'gilead']
in march, gilead drew ire from analysts for releasing an upbeat q&amp;a without any hard data for its latest trodelvy trial, putting into question whether the drug would be effective in a common form of breast cancer. now the data are finally here. #asco22 
The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs